ライフサイエンスコーパス: restenotic

1 y syndrome; 22% versus 19%), de novo (versus restenotic; 22% versus 14%), and graft body lesions (ver

2 total of 105 patients with de novo (70%) or restenotic (30%) lesions who were treated by stenting (6

3 Restenotic and atherosclerotic lesions often contain smo

4 actor-beta (TGF-beta) is highly expressed in restenotic and atherosclerotic lesions, and known to ind

5 for SMC migration during the development of restenotic and atherosclerotic lesions.

6 competing processes during the formation of restenotic and atherosclerotic lesions.

7 nase activity also were measured in the same restenotic and nonrestenotic vessels by use of a radiosu

8 s in collagen content and metabolism between restenotic and nonrestenotic vessels have not been exami

9 osclerotic rabbit model, collagen content in restenotic and nonrestenotic vessels was measured both b

10 gh a large percentage of the volume of human restenotic arterial lesions is occupied by extracellular

11 constituent of the loose myxoid ECM in human restenotic arteries and of the neointima in experimental

12 The loose myxoid ECM typical of human restenotic arteries demonstrated intense, diffuse staini

13 modeling associated with atherosclerotic and restenotic arteries.

14 ce neovascularization of atherosclerotic and restenotic arteries.

15 gene expression in human atherosclerotic and restenotic carotid arteries using in situ messenger RNA

16 clinical outcome 5 years after treatment of restenotic coronary arteries with catheter-based iridium

17 ation is safe and effective for treatment of restenotic coronary arteries.

18 role of vasa vasorum in atherosclerotic and restenotic coronary artery disease.

19 Mainstream anti-restenotic devices, such as drug-eluting stent (DES) and

20 potential targets for directed abrogation of restenotic disease and recapitulates the results of clin

21 lyzed human coronary atheroma in de novo and restenotic disease to identify targets of therapy that m

22 ed as candidates for selective inhibition of restenotic disease.

23 Using RVX-208 (an emerging anti-restenotic drug under clinical trials) as the model payl

24 The anti-restenotic effect of rapamycin in patients may be attrib

25 ry method available in the clinic to prevent restenotic failure of open vascular reconstructions.

26 study enrolled 208 patients with de novo or restenotic > or = 70% aorto-ostial renal artery stenoses

27 ies and veins as well as atherosclerotic and restenotic human coronary arteries for evidence of VEGF/

28 Univariate predictors were restenotic lesion (odds ratio [OR]: 2.47, confidence int

29 t multivariate predictors for late MACE were restenotic lesion (relative risk [RR] 1.33, p = 0.02), P

30 days of stenting, ostial lesion, stent for a restenotic lesion and diffuse type ISR.

31 ultivessel disease, treatment of an in-stent restenotic lesion), laboratory findings (low baseline he

32 ative angiographic location of the recurrent restenotic lesion, after treatment of in-stent restenosi

33 bute to the progression and development of a restenotic lesion, many signaling through a common pathw

34 Late restenotic lesions (> 4 years) resembled atheroma and ex

35 Early restenotic lesions (< 1.5 years) contained abundant type

36 ectable with immunohistochemistry in 4 of 13 restenotic lesions (31%) and in 3 of 37 de novo lesions

37 to stain atherectomy specimens from 29 human restenotic lesions (mean restenosis interval, 6.0+/-4.4

38 larly, final IVUS lumen CSA (p = 0.0001) and restenotic lesions (p = 0.006) were found to predict TLR

39 ravascular ultrasound (IVUS) (p = 0.001) and restenotic lesions (p = 0.01).

40 The majority (55%) of the restenotic lesions after IRT failure were focal (< or =1

41 oronary artery lesions (HR 1.46, p < 0.001), restenotic lesions at baseline (HR 1.58, p = 0.006), and

42 that cytomegalovirus (CMV) DNA is present in restenotic lesions from atherectomy specimens.

43 lagen-rich sclerotic content is increased in restenotic lesions from patients with DM.

44 atients undergoing optimal DCA of de novo or restenotic lesions in 3.0- to 4.5-mm native coronary art

45 novo atherosclerotic or post-endarterectomy restenotic lesions in native carotid arteries were enrol

46 was safe in select patients with de novo or restenotic lesions in native coronary arteries.

47 Patients with new or restenotic lesions in native upper-extremity arterioveno

48 hese results suggest that the development of restenotic lesions involves localized deposits of specif

49 Diminished TF expression in restenotic lesions may in part account for the lower com

50 ergoing percutaneous treatment of de novo or restenotic lesions of the superficial femoral or proxima

51 PIs were repeated in restenotic lesions until sustained success was obtained.

52 DNA from human atherosclerotic and restenotic lesions was used to test the hypothesis that

53 Results in restenotic lesions were similar.

54 Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents rather

55 ar de novo atherosclerotic and, potentially, restenotic lesions) is fueled by more effective second-g

56 lasty such as renal aorto-ostial lesions and restenotic lesions, as well as after a suboptimal balloo

57 ressed by neointimal VSMCs of human coronary restenotic lesions, but not in healthy vessels.

58 Off-label use was defined as use in restenotic lesions, lesions in a bypass graft, left main

59 rominent component in stented and nonstented restenotic lesions.

60 ographic restenosis after gamma radiation of restenotic lesions.

61 nd myocardial infarctions than nonaggressive restenotic lesions.

62 mal formation in atherosclerotic plaques and restenotic lesions.

63 group included 68 patients with 74 in-stent restenotic lesions.

64 e-tissue-containing myxoid region typical of restenotic lesions.

65 en more striking in (nonstented and stented) restenotic lesions.

66 expression of these factors in VSMCs within restenotic lesions.

67 is increased and MMP-1 is decreased in early restenotic lesions.

68 atheromatous plaques and the development of restenotic lesions.

69 he femoral-popliteal segment in de- novo and restenotic lesions.

70 athologies - a rare feat among existing anti-restenotic methods.

71 Our study suggests a potential anti-restenotic modality of resveratrol application suitable

72 lesion length from the original lesion or a restenotic narrowing tighter than the original.

73 parin (HEPACOAT) in patients with de novo or restenotic native coronary artery lesions treated with a

74 Resveratrol is a promising anti-restenotic natural drug but subject to low bioavailabili

75 produces durable inhibition of all three pro-restenotic pathologies - a rare feat among existing anti

76 livery of resveratrol on all three major pro-restenotic pathologies including intimal hyperplasia (IH

77 and with the stent's thrombogenicity and pro-restenotic potential, thereby indicating ways to clinica

78 ravascular ultrasound (IVUS), we studied 107 restenotic previously stented lesions in 98 patients bef

79 sting a possible role for macrophages in the restenotic process after percutaneous coronary intervent

80 ventions is one of the key components of the restenotic process.

81 esses inherent anti-atherosclerotic and anti-restenotic properties.

82 In this study, restenotic segments taken from 30 human peripheral arter

83 was treated with drug-eluting stents in both restenotic segments.

84 omposed of hypercellular tissue was lower in restenotic specimens from patients with DM than in reste

85 gen-rich sclerotic tissue area was larger in restenotic specimens from patients with DM than in reste

86 otic specimens from patients with DM than in restenotic specimens from patients without DM (19 +/- 6%

87 otic specimens from patients with DM than in restenotic specimens from patients without DM (77 +/- 9%

88 In restenotic specimens, VEGF/VPF immunostaining was more p

89 clinical outcome 3 years after treatment of restenotic stented coronary arteries with catheter-based

90 Restenotic stents had more tissue growth both within and

91 x lesions (long, tandem, severely calcified, restenotic, thrombotic, or ostial; total occlusions; bif

92 n occurred due to rotational ablation of the restenotic tissue and only 23% occurred after adjunct ba

93 l hypercellular tissue content is reduced in restenotic tissue from patients with DM.

94 We analyzed 29 coronary arterial in-stent restenotic tissue samples (14 left anterior descending c

95 on rate that has been associated with DCA of restenotic versus de novo lesions.

96 llagen content is significantly decreased in restenotic versus nonrestenotic vessels after angioplast

97 were differently expressed in human coronary restenotic versus primary lesions.

98 ntent was found to be significantly lower in restenotic vessels than in nonrestenotic vessels both bi